Gebran Khneizer, MD
Gastroenterology · Wichita, KSNPI 1386039477
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.9% of the total. Reporting peaked in 2024 at $1,252 and has fallen 50.9% since, to $614 in 2025.
Across 113 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$700
- Johnson & Johnson$496
- Intercept Pharmaceuticals, Inc.$403
- Ipsen Biopharmaceuticals, Inc$171
- Mallinckrodt Hospital Products Inc.$163
- Gilead$161
- plus $718 from 20 others
Across 1 payment — averaging $15,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$15K
What the payments were for
- Food & beverage$2,54591%
- Education$2669%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $700 |
| Johnson & Johnson | 28 | $496 |
| Intercept Pharmaceuticals, Inc. | 7 | $403 |
| Ipsen Biopharmaceuticals, Inc | 3 | $171 |
| Mallinckrodt Hospital Products Inc. | 2 | $163 |
| Gilead | 2 | $161 |
| Lilly USA, LLC | 5 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $100 |
| Pfizer | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Merck | 3 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Bristol Myers Squibb | 2 | $27 |
| Cook Medical LLC | 2 | $27 |
| Sanofi | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Celltrion USA Inc. | 1 | $20 |
| Biocon Biologics Inc | 1 | $19 |
| Mauna Kea Technologies, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
| QOL Medical, LLC | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Organon | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,811 in reported general payments places this provider in the 60th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 24 | $16,313 |
| Pantoprazole Sodium | 69 | $568 |
| Omeprazole | 36 | $436 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 22 | $310 |
| Esomeprazole Magnesium | 14 | $278 |
| Dicyclomine Hcl | 29 | $235 |
| Ondansetron OdtOndansetron | 12 | $217 |
| Famotidine | 13 | $159 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 14 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $700 | $16,31324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Wichita
- Mark BowlesWichita$11K
- Estephan ZayatWichita$10K
- Maria ChangWichita$6K
- Winnie Sheu WocWichita$6K
- William KilgoreWichita$5K
- Obada TayyemWichita$5K
- Saritha GorantlaWichita$3K
- Bassem MattaWichita$3K
- Michael LievensWichita$1K
- Natalie FarhaWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.